Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus

被引：82

作者：

Chinsangaram, J ^{[1
]}

Mason, PW ^{[1
]}

Grubman, MJ ^{[1
]}

机构：

[1] ARS, USDA, NAA, Plum Isl Anim Dis Ctr, Greenport, NY 11944 USA

来源：

VACCINE | 1998年 / 16卷 / 16期

关键词：

foot-and-mouth disease; attenuated vaccine; swine;

D O I：

10.1016/S0264-410X(98)00029-2

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Previously, we demonstrated that a genetically engineered variant of foot-and-mouth disease virus (FMDV) serotype A12 lacking the leader proteinase-coding region (A12-LLV2) was attenuated and induced an immune response that partially protected cattle from FMD. In this study A12-LLV2 was tested in swine as a live or chemically inactivated vaccine. Animals vaccinated with chemically inactivated A12-LLV2 or wild-type (WT) virus in oil adjuvant developed high levels of neutralizing antibodies and were protected from FMD upon challenge. Animals vaccinated with live A12-LLV2 did not exhibit signs of FMD, did not spread virus to other animals, developed a neutralizing antibody response and antibodies to nonstructural protein 3D, and were partially protected from FMD. Animals given a similar dose of chemically inactivated A12-LLV2 in the absence of adjuvant developed a poor immune response and were not protected from FMD, indicating that limited replication was responsible for the improved immune response found in animals vaccinated with live A12-LLV2. The results demonstrate the potential of A12-LLV2 as a live-attenuated vaccine as well as a safe source of antigen for chemically inactivated vaccines. (C) 1998 Elsevier Science Ltd. All rights reserved.

引用

页码：1516 / 1522

页数：7

共 28 条

[1]

Bachrach H. L., 1978, Viruses and environment, P299

[2] FOOT-AND-MOUTH DISEASE [J].

BACHRACH, HL .

ANNUAL REVIEW OF MICROBIOLOGY, 1968, 22 :201-+

[3] INACTIVATION OF VIRAL-ANTIGENS FOR VACCINE PREPARATION WITH PARTICULAR REFERENCE TO THE APPLICATION OF BINARY ETHYLENIMINE [J].

BAHNEMANN, HG .

VACCINE, 1990, 8 (04) :299-303

[4] DEVELOPMENTS IN FOOT-AND-MOUTH-DISEASE VACCINES [J].

BARTELING, SJ ;

VREESWIJK, J .

VACCINE, 1991, 9 (02) :75-88

[5] SUBTYPING OF EUROPEAN FOOT-AND-MOUTH-DISEASE VIRUS-STRAINS BY NUCLEOTIDE-SEQUENCE DETERMINATION [J].

BECK, E ;

STROHMAIER, K .

JOURNAL OF VIROLOGY, 1987, 61 (05) :1621-1629

[6] PORTRAITS OF VIRUSES - FOOT-AND-MOUTH-DISEASE VIRUS .8. [J].

BROOKSBY, JB .

INTERVIROLOGY, 1982, 18 (1-2) :1-23

[7] Pathogenesis of wild-type and leaderless foot-and-mouth disease virus in cattle [J].

Brown, CC ;

Piccone, ME ;

Mason, PW ;

McKenna, TSC ;

Grubman, MJ .

JOURNAL OF VIROLOGY, 1996, 70 (08) :5638-5641

[8] NEW APPROACHES TO VACCINATION AGAINST FOOT-AND-MOUTH-DISEASE [J].

BROWN, F .

VACCINE, 1992, 10 (14) :1022-1026

[9]

Cottral G E, 1965, Bull Off Int Epizoot, V63, P1607

[10] LEADER PROTEIN OF FOOT-AND-MOUTH-DISEASE VIRUS IS REQUIRED FOR CLEAVAGE OF THE P220 COMPONENT OF THE CAP-BINDING PROTEIN COMPLEX [J].

DEVANEY, MA ;

VAKHARIA, VN ;

LLOYD, RE ;

EHRENFELD, E ;

GRUBMAN, MJ .

JOURNAL OF VIROLOGY, 1988, 62 (11) :4407-4409

← 1 2 3 →